继发于布鲁顿酪氨酸激酶抑制剂治疗的眼表面原位鳞状上皮细胞瘤。

IF 2 4区医学 Q2 OPHTHALMOLOGY Eye & Contact Lens-Science and Clinical Practice Pub Date : 2024-11-01 Epub Date: 2024-09-20 DOI:10.1097/ICL.0000000000001129

Ryan F Bloomquist, Monali V Sakhalkar, Teresa E Fowler, Doan T Bloomquist

{"title":"继发于布鲁顿酪氨酸激酶抑制剂治疗的眼表面原位鳞状上皮细胞瘤。","authors":"Ryan F Bloomquist, Monali V Sakhalkar, Teresa E Fowler, Doan T Bloomquist","doi":"10.1097/ICL.0000000000001129","DOIUrl":null,"url":null,"abstract":"Abstract: Bruton tyrosine kinase (BTK) inhibitors have become an important therapeutic option in treating B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, a noted morbidity associated with their use is the potential for the development of second primary malignancy related to immunomodulation. In this case, we report a second primary malignancy of ocular surface squamous neoplasia (OSSN) owing to BTK therapy. The OSSN was successfully treated and has been monitored without recurrence. To our knowledge, this is the first case of OSSN secondary to BTK therapy.","PeriodicalId":50457,"journal":{"name":"Eye & Contact Lens-Science and Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocular Surface Squamous Neoplasia In Situ Secondary to Bruton Tyrosine Kinase Inhibitor Therapy.\",\"authors\":\"Ryan F Bloomquist, Monali V Sakhalkar, Teresa E Fowler, Doan T Bloomquist\",\"doi\":\"10.1097/ICL.0000000000001129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Bruton tyrosine kinase (BTK) inhibitors have become an important therapeutic option in treating B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, a noted morbidity associated with their use is the potential for the development of second primary malignancy related to immunomodulation. In this case, we report a second primary malignancy of ocular surface squamous neoplasia (OSSN) owing to BTK therapy. The OSSN was successfully treated and has been monitored without recurrence. To our knowledge, this is the first case of OSSN secondary to BTK therapy.\",\"PeriodicalId\":50457,\"journal\":{\"name\":\"Eye & Contact Lens-Science and Clinical Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye & Contact Lens-Science and Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ICL.0000000000001129\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye & Contact Lens-Science and Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICL.0000000000001129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

摘要：布鲁顿酪氨酸激酶（BTK）抑制剂已成为治疗包括非霍奇金淋巴瘤和慢性淋巴细胞白血病在内的B细胞恶性肿瘤的重要治疗选择。然而，与使用这些药物相关的一个显著的发病率是，可能会出现与免疫调节相关的第二原发性恶性肿瘤。在本病例中，我们报告了因 BTK 治疗而导致的眼表面鳞状上皮细胞瘤（OSSN）的第二原发性恶性肿瘤。该眼表鳞状上皮瘤已成功治愈，经监测未再复发。据我们所知，这是第一例继发于 BTK 治疗的眼表鳞状上皮瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ocular Surface Squamous Neoplasia In Situ Secondary to Bruton Tyrosine Kinase Inhibitor Therapy.

Abstract: Bruton tyrosine kinase (BTK) inhibitors have become an important therapeutic option in treating B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, a noted morbidity associated with their use is the potential for the development of second primary malignancy related to immunomodulation. In this case, we report a second primary malignancy of ocular surface squamous neoplasia (OSSN) owing to BTK therapy. The OSSN was successfully treated and has been monitored without recurrence. To our knowledge, this is the first case of OSSN secondary to BTK therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eye & Contact Lens-Science and Clinical Practice OPHTHALMOLOGY-

CiteScore

4.50

自引率

4.30%

发文量

150

审稿时长

6-12 weeks

期刊介绍： Eye & Contact Lens: Science and Clinical Practice is the official journal of the Contact Lens Association of Ophthalmologists (CLAO), an international educational association for anterior segment research and clinical practice of interest to ophthalmologists, optometrists, and other vision care providers and researchers. Focusing especially on contact lenses, it also covers dry eye disease, MGD, infections, toxicity of drops and contact lens care solutions, topography, cornea surgery and post-operative care, optics, refractive surgery and corneal stability (eg, UV cross-linking). Peer-reviewed and published six times annually, it is a highly respected scientific journal in its field.